XTX Topco Ltd Invests $621,000 in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

XTX Topco Ltd purchased a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,491 shares of the company’s stock, valued at approximately $621,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Seven Eight Capital LP acquired a new stake in SpringWorks Therapeutics in the second quarter valued at $1,854,000. E Fund Management Co. Ltd. increased its holdings in SpringWorks Therapeutics by 11.6% in the second quarter. E Fund Management Co. Ltd. now owns 9,467 shares of the company’s stock valued at $357,000 after purchasing an additional 981 shares during the period. Mutual of America Capital Management LLC increased its holdings in SpringWorks Therapeutics by 41.4% in the second quarter. Mutual of America Capital Management LLC now owns 116,915 shares of the company’s stock valued at $4,404,000 after purchasing an additional 34,260 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in SpringWorks Therapeutics by 14.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 535,083 shares of the company’s stock valued at $20,157,000 after purchasing an additional 69,227 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in SpringWorks Therapeutics by 56.9% in the second quarter. Envestnet Asset Management Inc. now owns 112,426 shares of the company’s stock valued at $4,235,000 after purchasing an additional 40,781 shares during the period.

Analysts Set New Price Targets

SWTX has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $76.00 price objective on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Wedbush reaffirmed an “outperform” rating and set a $77.00 price target (up previously from $75.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. Finally, JPMorgan Chase & Co. upped their price target on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $68.50.

SpringWorks Therapeutics Price Performance

SWTX stock opened at $32.88 on Tuesday. The stock has a market capitalization of $2.44 billion, a PE ratio of -6.40 and a beta of 0.79. The company’s 50-day moving average is $37.62 and its 200-day moving average is $41.10. SpringWorks Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.58. The company had revenue of $59.73 million for the quarter, compared to the consensus estimate of $34.42 million. SpringWorks Therapeutics’s revenue for the quarter was up 59732900.0% compared to the same quarter last year. During the same period last year, the company earned ($1.25) EPS. On average, analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.36 earnings per share for the current fiscal year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.